PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation

BRAF inhibitors (BRAFi) are standard of care for the treatment of BRAF V600 mutation-driven metastatic melanoma, but can lead to paradoxical activation of the mitogen-activated protein kinase (MAPK) signalling pathway. This can result in the promotion of precancerous lesions and secondary neoplasms,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer
Main Authors: Tutuka, Candani S. A., Andrews, Miles C., Mariadason, John M., Ioannidis, Paul, Hudson, Christopher, Cebon, Jonathan, Behren, Andreas
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Letter to the Editor
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5490236/
https://ncbi.nlm.nih.gov/pubmed/28659148
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-017-0684-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados